Relating to prior authorization for prescription drug benefits related to the treatment of neurodegenerative diseases.

SB 1525 would limit insurance companies in Texas from requiring more than one annual prior authorization for prescription drugs treating neurodegenerative diseases (like Alzheimer's or Parkinson's), autoimmune diseases, hemophilia, or Von Willebrand disease. It specifically allows insurers to require a prior authorization for a *new* prescription drug for a neurodegenerative disease, but not for ongoing treatment. The law would apply only to health plans delivered, issued, or renewed on or after January 1, 2026. This bill directly affects patients with these conditions who rely on prescription medications for treatment.